Imugene (ASX:IMU) Days Sales Outstanding: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Imugene Days Sales Outstanding?

Imugene's average Accounts Receivable for the six months ended in Jun. 2026 was A$2.21 Mil. Imugene's Revenue for the six months ended in Jun. 2026 was A$0.00 Mil.

The historical rank and industry rank for Imugene's Days Sales Outstanding or its related term are showing as below:

ASX:IMU's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 69.01
* Ranked among companies with meaningful Days Sales Outstanding only.

Imugene's Days Sales Outstanding stayed the same from Jun. 2025 () to Jun. 2026 ().

Imugene  (ASX:IMU) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Imugene Days Sales Outstanding Related Terms

Imugene Days Sales Outstanding Historical Data

* Premium members only.

The historical data trend for Imugene's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imugene Days Sales Outstanding Chart

Imugene Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Imugene Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ASX:IMU vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison

For the Biotechnology subindustry, Imugene's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imugene Days Sales Outstanding vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imugene's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Imugene's Days Sales Outstanding falls into.


Imugene Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Imugene's Days Sales Outstanding for the fiscal year that ended in Jun. 2026 is calculated as

Days Sales Outstanding (A: Jun. 2026 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2025 ) + Accounts Receivable (A: Jun. 2026 )) / count ) / Revenue (A: Jun. 2026 )*Days in Period
=( (0.782507 + 0.009562) / 2 ) / 0*365
=0.3960345 / 0*365
=N/A

Imugene's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding (Q: Jun. 2026 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2025 ) + Accounts Receivable (A: Jun. 2026 )) / count ) / Revenue (A: Jun. 2026 )*Days in Period
=( (4.413617 + 0.009562) / 2 ) / 0*365 / 2
=2.2115895 / 0*365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imugene Business Description

Other Exchanges IUGNF:USAILA:Germany
Address 4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.